erastin and abiraterone

Ferroptosis is a type of programmed cell death induced by the accumulation of lipid peroxidation and lipid reactive oxygen species in cells. It has been recently demonstrated that cancer cells are vulnerable to ferroptosis inducers (FIN). However, the therapeutic potential of FINs in prostate cancer in preclinical settings has not been explored. In this study, we demonstrate that mediators of ferroptosis, solute carrier family 7 member 11, SLC3A2, and glutathione peroxidase, are expressed in treatment-resistant prostate cancer. We further demonstrate that treatment-resistant prostate cancer cells are sensitive to two FINs, erastin and RSL3. Treatment with erastin and RSL3 led to a significant decrease in prostate cancer cell growth and migration

Topics: Amino Acid Transport System y+; Androgen Antagonists; Androstenes; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carbolines; Cell Line, Tumor; Drug Resistance, Neoplasm; Ferroptosis; Fusion Regulatory Protein 1, Heavy Chain; Humans; Male; Mice; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Phospholipid Hydroperoxide Glutathione Peroxidase; Piperazines; Prostate; Prostatic Neoplasms, Castration-Resistant; Xenograft Model Antitumor Assays